摘要目的 观察儿童近视眼局部使用0.01%阿托品滴眼液6个月的疗效及安全性。方法 选择2017-04至2018-03到战略支援部队特色医学中心眼科门诊儿童近视眼拟用0.01%阿托品滴眼液患者30例(59只眼)及同期仅配戴框架眼镜的儿童近视眼18例(36只眼),分别作为试验组和对照组进行观察,分析两组病例在使用药物后3、6个月时眼压、泪膜破裂时间(BUT)、泪河高度(TMH)以及干眼问卷调查评分情况。结果 试验组终末失访4例(8只眼),纳入统计分析26例(51眼)。(1)用药后6个月,试验组与对照组比较屈光度有统计学差异,试验组屈光度为(-2.81±1.25)D,对照组为(-3.38±1.24)D;(2)用药后6个月试验组与对照组比较,眼压[(20.18±5.21)mmHg vs. (20.97±5.12)mmHg]、BUT[(7.65±3.51)s vs. (7.21±3.12)s]、TMH[(0.24±0.05)mm vs. (0.26±0.05)mm]、干眼评分(4.62±0.66 vs. 4.65±0.64)等差异均无统计学意义;(3)用药6个月期间未发现畏光、看近困难、过敏等不良反应。结论 局部使用0.01%阿托品滴眼液6个月具有比较满意的疗效和安全性。
Abstract：Objective To observe the clinical effect and safety of 0.01% atropine eye drops among children with myopia. Methods Patients with myopia treated with 0.01% atropine eye drops were included in the study (30 cases, 59 eyes). 4 cases (8 eyes) were out of contact during the last follow-up, so 26 cases (51 eyes) were included in the statistical analysis. Meanwhile, other myopic children (18 cases, 36 eyes) who wore glasses only were selected as the control group. The changes of intraocular pressure, tear film break-up time (BUT), tear meniscus height (TMH), and dry eye questionnaire scores after three and after 6 months of treatment with eye drops were compared between the two groups.Results (1)There was statistically significant significance in diopter between the test group (-2.81±1.25) D and the control group (-3.38±1.24)D after six months of treatment. (2) There was no statistically significant significance in intraocular pressure [(20.18±5.21)mmHg vs. (20.97±5.12) mmHg], in BUT [(7.65±3.51)s vs. (7.21±3.12)s], in TMH [(0.24±0.05) mm vs. (0.26±0.05)mm], or in dry eye questionnaire scores (4.62±0.66 vs. 4.65±0.64) between the two groups. (3)No photophobia, near sightedness, allergy and other adverse reactions were observed during the six months of medication.Conclusions Six-month topical use of 0.01% atropine eye solution for 6 months can deliver satisfactory efficacy and safety.
Polling J R, Kok R G, Tideman J W, et al. Effectiveness study of atropine for progressive myopia in Europeans [J]. Eye (Lond), 2016, 30(7): 998-1004.
[2]
Grzybowski A, Armesto A, Szwajkowsk M, et al. The role of atropine eye drops in myopia control[J]. Curr Pharm Des, 2015, 21(32): 4718-4730.
[3]
Cooper J, Eisenberg N, Schulman E, et al. Maximum atropine dose without clinical signs or symptoms [J]. Optom Vis Sci, 2013, 90(12): 1467-1472.
[4]
Tong L, Huang X L, Koh A L, et al. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine[J]. Ophthalmology, 2009, 116(3): 572-579.
[5]
Chia A C, Chua W H, Cheung Y B, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%,0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2) [J]. Ophthalmology, 2012, 119(2): 347-354.
[6]
Chia A, Lu Q S, Tan D. Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops [J]. Ophthalmology, 2016, 123(2): 391-399.
[7]
李凤鸣,谢立信,朱秀安,等.中华眼科学[M].北京:人民卫生出版社, 2014.
[8]
Mcmonnies C W, Ho A, Wakefield D. Optimum dry eye classification using questionnaire responses[J]. Adv Exp Med Biol, 1998, 438: 835-838.
[9]
中华人民共和国国家卫生健康委员会. 近视防治指南,2018.
[10]
Gimbel H V. The control of myopia with atropine[J]. Can J Ophthalmol, 1973, 8(4): 527-532.
[11]
Li S M, Wu S S, Kang M T, et al. Atropine slows myopia progression more in Asian than white children by meta-analysis[J]. Optom Vis Sci, 2014, 91(3): 342-350.
[12]
Chua W H, Balakrishnan V, Chan Y H, et al. Atropine for the treatment of childhood myopia[J]. Ophthalmology, 2006, 113(12):2285-2291.
[13]
Pineles S L, Kraker R T, Vanderveen D K, et al. Atropine for the prevention of myopia progression in children: a report by the American Academy of Ophthalmology[J]. Ophthalmology, 2017, 124(12):1857-1866.
[14]
Huang J, Wen D, Wang Q, et al. Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis [J]. Ophthalmology, 2016, 123(4): 697.
2021, Vol. 32 
